Brand Name

Anktiva

Generic Name
Nogapendekin
View Brand Information
FDA approval date: May 06, 2024
Classification: Interleukin-15 Receptor Agonist
Form: Solution

What is Anktiva (Nogapendekin)?

ANKTIVA in combination with Bacillus Calmette-Guérin is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. ANKTIVA is an interleukin-15 receptor agonist indicated with Bacillus Calmette-Guérin for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Summary: This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being treated with adoptive cellular therapy (ACT) using T-cell receptor therapy (T-CRT). Synovial sarcoma is a rare, slow-growing cancer that affects the soft tissues, like muscle...

A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)

Summary: The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in this study are: * PD-L1 t-haNK cell therapy (a NK cell therapy infusion) * NAI (a type o...

Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID

Summary: This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.

Related Latest Advances